4D Molecular Therapeutics, Inc.

NasdaqGS:FDMT Rapporto sulle azioni

Cap. di mercato: US$420.7m

4D Molecular Therapeutics Crescita futura

Future criteri di controllo 2/6

4D Molecular Therapeutics's earnings are forecast to decline at 10.7% per annum while its annual revenue is expected to grow at 47.8% per year. EPS is expected to decline by 2.3% per annum.

Informazioni chiave

-10.7%

Tasso di crescita degli utili

-2.3%

Tasso di crescita dell'EPS

Biotechs crescita degli utili27.1%
Tasso di crescita dei ricavi47.8%
Rendimento futuro del capitale proprion/a
Copertura analitica

Good

Ultimo aggiornamento17 Oct 2024

Aggiornamenti recenti sulla crescita futura

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates

Nov 12
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates

Recent updates

4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure

Oct 04

4D Molecular Therapeutics (NASDAQ:FDMT) Is In A Good Position To Deliver On Growth Plans

Aug 10
4D Molecular Therapeutics (NASDAQ:FDMT) Is In A Good Position To Deliver On Growth Plans

4D Molecular Therapeutics: R100 Vector Pushes Forward To Bring Q4 Of 2024 DME Data

Jul 19

4D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution

Apr 29

4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm

Feb 06

4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024

Jan 25

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates

Nov 12
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates

We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

Nov 08
We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation

May 08
Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation

We're Keeping An Eye On 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

Sep 29
We're Keeping An Eye On 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

4D Molecular Therapeutics GAAP EPS of -$0.87, revenue of $0.16M

Aug 11

Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation

Jun 11
Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:FDMT - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/20265-197-215N/A5
12/31/20257-172-198-1188
12/31/20245-148-172-889
6/30/202420-110-87-85N/A
3/31/202420-105-79-77N/A
12/31/202321-101-79-76N/A
9/30/202322-96-77-73N/A
6/30/20232-111-98-93N/A
3/31/20232-110-97-91N/A
12/31/20223-107-98-87N/A
9/30/20222-105-102-86N/A
6/30/20223-102-97-81N/A
3/31/202217-81-92-77N/A
12/31/202118-71-78-69N/A
9/30/202117-67-69-65N/A
6/30/202123-52-64-62N/A
3/31/202112-60-53-52N/A
12/31/202014-57-52-51N/A
9/30/202017-52-43-42N/A
6/30/202010-61-42-40N/A
3/31/20208-54-45-42N/A
12/31/20197-49-40-37N/A
9/30/20199-35-36-33N/A
6/30/201913-21-29-27N/A
3/31/201914-15-23-22N/A
12/31/201814-10-17-16N/A
12/31/20176-11N/A8N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: FDMT is forecast to remain unprofitable over the next 3 years.

Guadagni vs Mercato: FDMT is forecast to remain unprofitable over the next 3 years.

Guadagni ad alta crescita: FDMT is forecast to remain unprofitable over the next 3 years.

Ricavi vs Mercato: FDMT's revenue (47.8% per year) is forecast to grow faster than the US market (8.9% per year).

Ricavi ad alta crescita: FDMT's revenue (47.8% per year) is forecast to grow faster than 20% per year.


Previsioni di crescita dell'utile per azione


Rendimento futuro del capitale proprio

ROE futuro: Insufficient data to determine if FDMT's Return on Equity is forecast to be high in 3 years time


Scoprire le aziende in crescita